Trials / Unknown
UnknownNCT05653180
IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer
A Single Arm,Multi-center,Phase Ib/II Clinical Study Evaluating IBI310 Combined With Sintilimab in Patients With Advanced Biliary Tract Cance(BTC)
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This research study is designed to establish whether the combination of IBI310 \& Sintilimab has efficacy in patients with advanced BTC
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI310 | 2mg/kg IV,3 weeks later, 1mg/kg IV Q6W |
| DRUG | sintilimab | 200mg IV Q3W |
Timeline
- Start date
- 2023-03-10
- Primary completion
- 2023-12-31
- Completion
- 2024-06-01
- First posted
- 2022-12-16
- Last updated
- 2023-04-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05653180. Inclusion in this directory is not an endorsement.